메뉴 건너뛰기




Volumn 124, Issue 8, 2014, Pages 3601-3611

RAS interaction with PI3K p110α is required for tumor-induced angiogenesis

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, MOUSE; RAS PROTEIN;

EID: 84905453351     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74134     Document Type: Article
Times cited : (65)

References (51)
  • 2
    • 0028074316 scopus 로고
    • Phosphatidylinositol-3-OH kinase as a direct target of Ras
    • Rodriguez-Viciana P, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370(6490):527-532.
    • (1994) Nature , vol.370 , Issue.6490 , pp. 527-532
    • Rodriguez-Viciana, P.1
  • 3
    • 0030911052 scopus 로고    scopus 로고
    • Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
    • Rodriguez-Viciana P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89(3):457-467.
    • (1997) Cell , vol.89 , Issue.3 , pp. 457-467
    • Rodriguez-Viciana, P.1
  • 5
    • 34249026448 scopus 로고    scopus 로고
    • Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice
    • Gupta S, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129(5):957-968.
    • (2007) Cell , vol.129 , Issue.5 , pp. 957-968
    • Gupta, S.1
  • 6
    • 84887532497 scopus 로고    scopus 로고
    • Requirement for interaction of PI 3-kinase p110α with RAS in lung tumor maintenance
    • Castellano E, et al. Requirement for interaction of PI 3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell. 2013;24(5):617-630.
    • (2013) Cancer Cell. , vol.24 , Issue.5 , pp. 617-630
    • Castellano, E.1
  • 7
    • 84874650275 scopus 로고    scopus 로고
    • Development of PI3K inhibitors: Lessons learned from early clinical trials
    • Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
    • (2013) Nat Rev Clin Oncol. , vol.10 , Issue.3 , pp. 143-153
    • Rodon, J.1    Dienstmann, R.2    Serra, V.3    Tabernero, J.4
  • 8
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657-667.
    • (2013) Clin Cancer Res. , vol.19 , Issue.3 , pp. 657-667
    • Mao, M.1
  • 9
    • 84866930352 scopus 로고    scopus 로고
    • Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
    • Roberts PJ, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012;18(19):5290-5303.
    • (2012) Clin Cancer Res. , vol.18 , Issue.19 , pp. 5290-5303
    • Roberts, P.J.1
  • 10
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • Villanueva J, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
    • (2010) Cancer Cell. , vol.18 , Issue.6 , pp. 683-695
    • Villanueva, J.1
  • 11
    • 0037264633 scopus 로고    scopus 로고
    • Targeting RAS signalling pathways in cancer therapy
    • Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
    • (2003) Nat Rev Cancer , vol.3 , Issue.1 , pp. 11-22
    • Downward, J.1
  • 14
    • 58149345546 scopus 로고    scopus 로고
    • Co-evolution of tumor cells and their microenvironment
    • Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25(1):30-38.
    • (2009) Trends Genet. , vol.25 , Issue.1 , pp. 30-38
    • Polyak, K.1    Haviv, I.2    Campbell, I.G.3
  • 15
    • 33645739790 scopus 로고    scopus 로고
    • Tumor stroma and regulation of cancer development
    • Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
    • (2006) Annu Rev Pathol. , vol.1 , pp. 119-150
    • Tlsty, T.D.1    Coussens, L.M.2
  • 16
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
    • (1971) N Engl J Med. , vol.285 , Issue.21 , pp. 1182-1186
    • Folkman, J.1
  • 18
    • 33750826279 scopus 로고    scopus 로고
    • The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
    • Zhao JJ, et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006;103(44):16296-16300.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , Issue.44 , pp. 16296-16300
    • Zhao, J.J.1
  • 19
    • 0033574429 scopus 로고    scopus 로고
    • Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase
    • Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274(16):10963-10968.
    • (1999) J Biol Chem. , vol.274 , Issue.16 , pp. 10963-10968
    • Bi, L.1    Okabe, I.2    Bernard, D.J.3    Wynshaw-Boris, A.4    Nussbaum, R.L.5
  • 20
    • 0038363443 scopus 로고    scopus 로고
    • Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
    • Cao R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9(5):604-613.
    • (2003) Nat Med. , vol.9 , Issue.5 , pp. 604-613
    • Cao, R.1
  • 21
    • 84869777544 scopus 로고    scopus 로고
    • + regulatory T cells impairs mouse melanoma growth
    • + regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001-2016.
    • (2012) J Exp Med. , vol.209 , Issue.11 , pp. 2001-2016
    • Hansen, W.1
  • 22
    • 84860366086 scopus 로고    scopus 로고
    • Antiangiogenic therapy - Evolving view based on clinical trial results
    • Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012;9(5):297-303.
    • (2012) Nat Rev Clin Oncol. , vol.9 , Issue.5 , pp. 297-303
    • Jayson, G.C.1    Hicklin, D.J.2    Ellis, L.M.3
  • 23
    • 67649909568 scopus 로고    scopus 로고
    • Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
    • Hauschild A, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-2830.
    • (2009) J Clin Oncol. , vol.27 , Issue.17 , pp. 2823-2830
    • Hauschild, A.1
  • 24
    • 77955887676 scopus 로고    scopus 로고
    • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    • Kindler HL, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-3622.
    • (2010) J Clin Oncol. , vol.28 , Issue.22 , pp. 3617-3622
    • Kindler, H.L.1
  • 25
    • 65549150854 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
    • Van Cutsem E, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231-2237.
    • (2009) J Clin Oncol. , vol.27 , Issue.13 , pp. 2231-2237
    • Van Cutsem, E.1
  • 26
    • 84861690508 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    • Kelly WK, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534-1540.
    • (2012) J Clin Oncol. , vol.30 , Issue.13 , pp. 1534-1540
    • Kelly, W.K.1
  • 27
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
    • (2006) N Engl J Med. , vol.355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1
  • 28
    • 77951639655 scopus 로고    scopus 로고
    • Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    • Scagliotti G, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(11):1835-1842.
    • (2010) J Clin Oncol. , vol.28 , Issue.11 , pp. 1835-1842
    • Scagliotti, G.1
  • 29
    • 84863936062 scopus 로고    scopus 로고
    • Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
    • Scagliotti GV, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070-2078.
    • (2012) J Clin Oncol. , vol.30 , Issue.17 , pp. 2070-2078
    • Scagliotti, G.V.1
  • 30
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335- 2342.
    • (2004) N Engl J Med. , vol.350 , Issue.23 , pp. 2335-2342
    • Hurwitz, H.1
  • 31
    • 84856253589 scopus 로고    scopus 로고
    • Bevacizumab added to neoadjuvant chemotherapy for breast cancer
    • Bear HD, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310-320.
    • (2012) N Engl J Med. , vol.366 , Issue.4 , pp. 310-320
    • Bear, H.D.1
  • 32
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
    • (2007) N Engl J Med. , vol.357 , Issue.26 , pp. 2666-2676
    • Miller, K.1
  • 33
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • Robert NJ, et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
    • (2011) J Clin Oncol. , vol.29 , Issue.10 , pp. 1252-1260
    • Robert, N.J.1
  • 34
    • 84856291930 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
    • von Minckwitz G, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299-309.
    • (2012) N Engl J Med. , vol.366 , Issue.4 , pp. 299-309
    • Von Minckwitz, G.1
  • 35
    • 84855161152 scopus 로고    scopus 로고
    • Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
    • Cortes J, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann OncolAnn Oncol. 2012;23(5):1130-1137.
    • (2012) Ann OncolAnn Oncol. , vol.23 , Issue.5 , pp. 1130-1137
    • Cortes, J.1
  • 36
    • 79551520348 scopus 로고    scopus 로고
    • Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis
    • Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. J Am Med Assoc. 2011;305(5):487-494.
    • (2011) J Am Med Assoc. , vol.305 , Issue.5 , pp. 487-494
    • Ranpura, V.1    Hapani, S.2    Wu, S.3
  • 37
    • 79957773120 scopus 로고    scopus 로고
    • Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer
    • Park SY, Lee H-S, Jang H-J, Lee GK, Chung KY, Zo JI. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thoracic Surg. 2011;91(6):1668-1673.
    • (2011) Ann Thoracic Surg. , vol.91 , Issue.6 , pp. 1668-1673
    • Park, S.Y.1    Lee, H.-S.2    Jang, H.-J.3    Lee, G.K.4    Chung, K.Y.5    Zo, J.I.6
  • 38
    • 44349119736 scopus 로고    scopus 로고
    • Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration
    • Graupera M, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008;453(7195):662-666.
    • (2008) Nature , vol.453 , Issue.7195 , pp. 662-666
    • Graupera, M.1
  • 39
    • 51349169062 scopus 로고    scopus 로고
    • K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis
    • Liu L, Zhu S, Gong Z, Low BC. K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis. PLoS One. 2008;3(8):e2850.
    • (2008) PLoS One , vol.3 , Issue.8
    • Liu, L.1    Zhu, S.2    Gong, Z.3    Low, B.C.4
  • 40
    • 84885440456 scopus 로고    scopus 로고
    • Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
    • Soler A, et al. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med. 2013;210(10):1937-1945.
    • (2013) J Exp Med. , vol.210 , Issue.10 , pp. 1937-1945
    • Soler, A.1
  • 41
    • 80053493427 scopus 로고    scopus 로고
    • Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis
    • Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130-6139.
    • (2011) Clin Cancer Res. , vol.17 , Issue.19 , pp. 6130-6139
    • Lieu, C.1    Heymach, J.2    Overman, M.3    Tran, H.4    Kopetz, S.5
  • 42
    • 0037906432 scopus 로고    scopus 로고
    • Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis
    • Giavazzi R, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003;162(6):1913-1926.
    • (2003) Am J Pathol. , vol.162 , Issue.6 , pp. 1913-1926
    • Giavazzi, R.1
  • 43
    • 0027053487 scopus 로고
    • Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
    • Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189(2):824-831.
    • (1992) Biochem Biophys Res Commun. , vol.189 , Issue.2 , pp. 824-831
    • Pepper, M.S.1    Ferrara, N.2    Orci, L.3    Montesano, R.4
  • 44
    • 84866856702 scopus 로고    scopus 로고
    • Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis
    • Cao R, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A. 2012;109(39):15894- 15899.
    • (2012) Proc Natl Acad Sci U S A , vol.109 , Issue.39 , pp. 15894-15899
    • Cao, R.1
  • 45
    • 84857008164 scopus 로고    scopus 로고
    • Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma
    • Finn RS, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(7):2090-2098.
    • (2012) Clin Cancer Res. , vol.18 , Issue.7 , pp. 2090-2098
    • Finn, R.S.1
  • 46
    • 84864955678 scopus 로고    scopus 로고
    • A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
    • Doebele RC, et al. A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012;23(8):2094-2102.
    • (2012) Ann Oncol. , vol.23 , Issue.8 , pp. 2094-2102
    • Doebele, R.C.1
  • 48
    • 67749101418 scopus 로고    scopus 로고
    • IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions
    • Airoldi I, et al. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One. 2009;4(7):e6119.
    • (2009) PLoS One , vol.4 , Issue.7
    • Airoldi, I.1
  • 49
    • 0035869599 scopus 로고    scopus 로고
    • IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyteendothelial cell cross-talk
    • Strasly M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyteendothelial cell cross-talk. J Immunol. 2001;166(6):3890-3899.
    • (2001) J Immunol. , vol.166 , Issue.6 , pp. 3890-3899
    • Strasly, M.1
  • 50
    • 80355131976 scopus 로고    scopus 로고
    • Protective and pathogenic functions of macrophage subsets
    • Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737.
    • (2011) Nat Rev Immunol. , vol.11 , Issue.11 , pp. 723-737
    • Murray, P.J.1    Wynn, T.A.2
  • 51
    • 34248172324 scopus 로고    scopus 로고
    • Altered macrophage differentiation and immune dysfunction in tumor development
    • Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155-1166.
    • (2007) J Clin Invest. , vol.117 , Issue.5 , pp. 1155-1166
    • Sica, A.1    Bronte, V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.